Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrografin in the Management of Fecal Impaction
NCT02784093Phase 2Unknown
- Sponsor
- Jinling Hospital
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diatrizoate meglumine + diatrizoate sodium in fecal impaction (2 arms), sponsored by Jinling Hospital. Primary endpoints: Proportion of patients having successful disimpaction at 6 days and Time when patients having successful disimpaction at 6 days. Status: unknown.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
fecal impaction
Beyond the preview
Go deeper on NCT02784093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784093.